Nice tool for checking the drug interaction. You can enter up to 20 drugs.
This is another one:
Another great free online book. Enjoy!
Chapter 1 – Section 1: First Principles of Gastroenterology.
Just to give you a heads up that you can read Harrison’s online for FREE. Aren’t we lucky that in nowadays we have access to any information we need. No more excuses such as “I have no money for books” or “they don’t ship this book to my country”. Harrison’s is more the enough for any medical student to ace on any exam…just kidding, Harrison’s is a bit too much if you study for USMLE, but it doesn’t hurt if you read it.
AccessMedicine | Harrison’s Principles of Internal Medicine, 17e.
It is time to celebrate. The Facebook group USMLEMD has 300 members. My blogging and RSS philosophy is,”never push the readers to subscribe”. I hate when some bloggers offer a “free” e-book, or “free” something else, ONLY IF you subscribe to their blog or website.
So, I am pretty happy with number of readers I have as long as they are happy. I don’t want to push anybody. If you like the content of the website, feel free to read, use, and share it.
It is also time to give you a heads up that I will be giving away copies of the new Conrad Fischer’s (@seefisch) book “Routine Miracles”. Actually not me, but Kaplan publishing will give away the books to the readership of USMLEMD. In one the future posts I will disclose more details about how everything with the books will work out.
USMLE – Let’s help each other to crush the Boards! | Facebook.
I have been looking for a lab coat for some time. One day, I saw a doctor from another floor. His lab coat really looked nice and fitted him well. The lab coats they offer free from the hospital look funny. I asked him where did he buy the lab coat and he gave me this website. You can also order it with embroidery, which is cool.
LabWear.com – lab coats, men’s lab coats, women’s lab coats with free embroidery.
The National Board of Medical Examiners® NBME offers web-based self-assessments to help medical students and graduates evaluate their readiness for the computer-based components of the United States Medical Licensing Examination USMLE. The content of the Comprehensive Basic Science Self-Assessment CBSSA resembles the content of USMLE Step 1, while the content of the Comprehensive Clinical Science Self-Assessment CCSSA resembles the content of USMLE Step 2 Clinical Knowledge CK.
ABSTRACT: Background The development of a safe and effective vaccine against the human immunodeficiency virus type 1 HIV-1 is critical to pandemic control.Methods In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine ALVAC-HIV [vCP1521] plus two booster injections of a recombinant glycoprotein 120 subunit vaccine AIDSVAX B/E. The vaccine and placebo injections were administered to 16,402 healthy men and women between the ages of 18 and 30 years in Rayong and Chon Buri provinces in Thailand. The volunteers, primarily at heterosexual risk for HIV infection, were monitored for the coprimary end points: HIV-1 infection and early HIV-1 viremia, at the end of the 6-month vaccination series and every 6 months thereafter for 3 years.Results In the intention-to-treat analysis involving 16,402 subjects, there was a trend toward the prevention of HIV-1 infection among the vaccine recipients, with a vaccine efficacy of 26.4% 95% confidence interval [CI], –4.0 to 47.9; P=0.08. In the per-protocol analysis involving 12,452 subjects, the vaccine efficacy was 26.2% 95% CI, –13.3 to 51.9; P=0.16. In the modified intention-to-treat analysis involving 16,395 subjects with the exclusion of 7 subjects who were found to have had HIV-1 infection at baseline, the vaccine efficacy was 31.2% 95% CI, 1.1 to 51.2; P=0.04. Vaccination did not affect the degree of viremia or the CD4+ T-cell count in subjects in whom HIV-1 infection was subsequently diagnosed.Conclusions This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk. Vaccination did not affect the viral load or CD4+ count in subjects with HIV infection. Although the results show only a modest benefit, they offer insight for future research. ClinicalTrials.gov number, NCT00223080 [ClinicalTrials.gov] .
via NEJM — Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand.
